ArticleOncogene2010
Epigenetic regulation of the human p53 gene promoter by the CTCF transcription factor in transformed cell lines.
Article in Oncogene, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 94 citations in OpenAlex.
- CircARAP2 controls sMICA-induced NK cell desensitization by erasing CTCF/PRC2-induced suppression in early endosome marker RAB5A.Cellular and molecular life sciences : CMLS · 2024Article
- Differential DNA methylation and CTCF binding between the ESR1 promoter a of MCF-7 and MDA-MB-231 breast cancer cells.Molecular biology reports · 2024Article
- Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling.Signal transduction and targeted therapy · 2023Article
- Survival is associated with repressive histone trimethylation markers in both HR-positive HER2-negative and triple-negative breast cancer patients.Virchows Archiv : an international journal of pathology · 2023Article
- CTCF deletion alters the pluripotency and DNA methylation profile of human iPSCs.Frontiers in cell and developmental biology · 2023Article
- Zinc finger protein 280C contributes to colorectal tumorigenesis by maintaining epigenetic repression at H3K27me3-marked loci.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
- Mechanisms of TP53 Pathway Inactivation in Embryonic and Somatic Cells-Relevance for Understanding (Germ Cell) Tumorigenesis.International journal of molecular sciences · 2021Review
- Epigenomic regulation of human T-cell leukemia virus by chromatin-insulator CTCF.PLoS pathogens · 2021Article
- KMT5c modulates adipocyte thermogenesis by regulatingProceedings of the National Academy of Sciences of the United States of America · 2020Article
- CTCF loss mediates unique DNA hypermethylation landscapes in human cancers.Clinical epigenetics · 2020Article
- NPM1c impedes CTCF functions through cytoplasmic mislocalization in acute myeloid leukemia.Leukemia · 2020Article
- MeCP2 and Chromatin Compartmentalization.Cells · 2020Review
- CTCF mediates chromatin looping via N-terminal domain-dependent cohesin retention.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Downregulation of p53 by Insufficient CTCF in CD4Frontiers in immunology · 2020Article
- DNA Methylation Activates TP73 Expression in Hepatocellular Carcinoma and Gastrointestinal Cancer.Scientific reports · 2019Article
- RNA Interactions Are Essential for CTCF-Mediated Genome Organization.Molecular cell · 2019Article
- Genomic Comparison of Endometrioid Endometrial Carcinoma and Its Precancerous Lesions in Chinese Patients by High-Depth Next Generation Sequencing.Frontiers in oncology · 2019Article
- FAST-1 antisense RNA epigenetically alters FXN expression.Scientific reports · 2018Article
- Article
- Identification and validation of colorectal neoplasia-specific methylation biomarkers based on CTCF-binding sites.Oncotarget · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Epigenetic silencing of tumor suppressor gene promoters has become a more frequent phenomenon in cancer than previously anticipated. In this study we addressed the mechanisms involved in the protection of the p53 tumor suppressor gene against epigenetic silencing in human transformed cell lines. We characterized a binding site for the CCCTC-binding factor (CTCF) in the human p53 gene promoter that contributes to its transcriptional expression, and has the ability to maintain this regulatory element in a local open chromatin configuration. In the absence of CTCF we observe the incorporation of repressive histone marks, such as H3K9me3, H3K27me3 and H4K20me3, in different sub-domains of the upstream regulatory sequence. This evidence suggests that CTCF protects the p53 gene promoter against repressive histone marks. Notably, no apparent direct correlation between repression and DNA hypermethylation has been detected. Together, we present evidence supporting the relevant role of CTCF in the epigenetic regulation of tumor suppressor genes and cancer. We propose that CTCF is a strategic component responsible for the maintenance and segregation of epigenetic traits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.